News

Success Story: Patients at the Forefront of DCIS De‑Escalation Through the LORD Trial  May 18, 2026 The LORD trial (LOw Risk Ductal carcinoma in situ – DCIS) – a landmark international study that places patients at the center of research design, decision-making, and dissemination was developed through close collaboration between researchers and patient advocates. The LORD trial demonstrates how meaningful patient partnership can reshape clinical research and improve relevance, feasibility, and impact.  The […]

RTFCCR and Anticancer Fund Launch Ingenious, a Joint Call to Support Innovative Treatment Strategies to Improve Cancer Survival  May 8, 2026 The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and the Anticancer Fund (ACF) have launched Ingenious, a new joint Call for Research Projects (CfRP) aimed at supporting academic‑led clinical trials evaluating whether treatment strategies that incorporate predictive information can improve patient

Amplifying Patient Voice: Success Story March 27, 2026 Showcasing Outstanding Patient Partnership in the HYPERION CCA Study  We are delighted to spotlight the partnership between HYPERION CCA research team, and the Cholangiocarcinoma Foundation (CCF). ​The HYPERION CCA study is led by Dr. Eugene Koay at The University of Texas MD Anderson Cancer Center, one of our grantees.​   This research team

Grantee Spotlight: Developing New Immune-Based Treatments for Aggressive Brain Cancer March 24, 2026 The Challenge Malignant brain tumors, such as glioblastoma, are among the most aggressive cancers in adults. Despite maximal standard therapy – surgery followed by radiotherapy and temozolomide chemotherapy – most patients live only about 15 to 16 months after diagnosis. For decades, progress has been slow, and new treatment approaches are